Board of Trustees of The Leland Stanford Junior University’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

Board of Trustees of The Leland Stanford Junior University’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-265,670	Closed	-$35M	–	32
2020 Q4	$35M	Hold	265,670	–	–	2.46%	6
2020 Q3	$13.4M	Hold	265,670	–	–	5.17%	8
2020 Q2	$12.7M	Hold	265,670	–	–	10.9%	3
2020 Q1	$13M	Hold	265,670	–	–	2.63%	6
2019 Q4	$15.2M	Hold	265,670	–	–	1.85%	6
2019 Q3	$9.56M	Hold	265,670	–	–	1.04%	7
2019 Q2	$8.26M	Hold	265,670	–	–	1.15%	5
2019 Q1	$6.23M	Hold	265,670	–	–	0.87%	6
2018 Q4	$3.66M	Hold	265,670	–	–	0.44%	9
2018 Q3	$2.65M	Buy	265,670 +86,598	+48%	+$1.42M	0.34%	9
2018 Q2	$3.64M	Buy	+179,072	New	+$3.75M	0.35%	9

Board of Trustees of The Leland Stanford Junior University's EIDX Position: Q1 2021 in Review

Board of Trustees of The Leland Stanford Junior University sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 265,670 shares — an estimated $35M sold.

Board of Trustees of The Leland Stanford Junior University first reported a position in EIDX in Q2 2018 and held it in 11 quarters. The position peaked at $35M in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

Board of Trustees of The Leland Stanford Junior University reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Board of Trustees of The Leland Stanford Junior University sold 265,670 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $35M.
Board of Trustees of The Leland Stanford Junior University first reported a position in Eidos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 11 quarters.
Board of Trustees of The Leland Stanford Junior University's Eidos Therapeutics, Inc. Common Stock position peaked at $35M in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Board of Trustees of The Leland Stanford Junior University's 13F filing for Q1 2021, filed 14 May 2021.